349 related articles for article (PubMed ID: 29284493)
1. Impact on healthcare resource utilization of multiple sclerosis in Spain.
Sicras-Mainar A; Ruíz-Beato E; Navarro-Artieda R; Maurino J
BMC Health Serv Res; 2017 Dec; 17(1):854. PubMed ID: 29284493
[TBL] [Abstract][Full Text] [Related]
2. Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability.
Casado V; Martínez-Yélamos S; Martínez-Yélamos A; Carmona O; Alonso L; Romero L; Moral E; Gubieras L; Arbizu T
BMC Health Serv Res; 2006 Nov; 6():143. PubMed ID: 17078879
[TBL] [Abstract][Full Text] [Related]
3. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.
da Silva NL; Takemoto MLS; Damasceno A; Fragoso YD; Finkelsztejn A; Becker J; Gonçalves MVM; Tilbery C; de Oliveira EML; Callegaro D; Boulos FC
BMC Health Serv Res; 2016 Mar; 16():102. PubMed ID: 27009599
[TBL] [Abstract][Full Text] [Related]
4. Direct and indirect economic consequences of multiple sclerosis in Ireland.
Fogarty E; Walsh C; McGuigan C; Tubridy N; Barry M
Appl Health Econ Health Policy; 2014 Dec; 12(6):635-45. PubMed ID: 25227118
[TBL] [Abstract][Full Text] [Related]
5. Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US.
Jones E; Pike J; Marshall T; Ye X
BMC Health Serv Res; 2016 Jul; 16():294. PubMed ID: 27443278
[TBL] [Abstract][Full Text] [Related]
6. Costs and quality of life of multiple sclerosis in Spain.
Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
[TBL] [Abstract][Full Text] [Related]
7. Estimate of the cost of multiple sclerosis in Spain by literature review.
Fernández O; Calleja-Hernández MA; Meca-Lallana J; Oreja-Guevara C; Polanco A; Pérez-Alcántara F
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):321-333. PubMed ID: 28726515
[TBL] [Abstract][Full Text] [Related]
8. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
9. Health status and costs of ambulatory patients with multiple sclerosis in Hungary.
Péntek M; Gulácsi L; Rózsa C; Simó M; Iljicsov A; Komoly S; Brodszky V
Ideggyogy Sz; 2012 Sep; 65(9-10):316-24. PubMed ID: 23126217
[TBL] [Abstract][Full Text] [Related]
10. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis.
Ruutiainen J; Viita AM; Hahl J; Sundell J; Nissinen H
J Med Econ; 2016; 19(1):21-33. PubMed ID: 26360615
[TBL] [Abstract][Full Text] [Related]
11. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.
Karampampa K; Gustavsson A; Miltenburger C; Kindundu CM; Selchen DH
J Popul Ther Clin Pharmacol; 2012; 19(1):e11-25. PubMed ID: 22247419
[TBL] [Abstract][Full Text] [Related]
12. Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
[TBL] [Abstract][Full Text] [Related]
13. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
14. New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain.
Oreja-Guevara C; Kobelt G; Berg J; Capsa D; Eriksson J;
Mult Scler; 2017 Aug; 23(2_suppl):166-178. PubMed ID: 28643597
[TBL] [Abstract][Full Text] [Related]
15. Burden of a multiple sclerosis relapse: the patient's perspective.
Oleen-Burkey M; Castelli-Haley J; Lage MJ; Johnson KP
Patient; 2012; 5(1):57-69. PubMed ID: 22217263
[TBL] [Abstract][Full Text] [Related]
16. Costs and quality of life of multiple sclerosis in Germany.
Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
[TBL] [Abstract][Full Text] [Related]
17. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain.
Casado V; Romero L; Gubieras L; Alonso L; Moral E; Martinez-Yelamos S; Martinez-Yelamos A; Carmona O; Arbizu T
Mult Scler; 2007 Jul; 13(6):800-4. PubMed ID: 17613609
[TBL] [Abstract][Full Text] [Related]
18. Costs and quality of life of multiple sclerosis in Italy.
Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
[TBL] [Abstract][Full Text] [Related]
19. Costs and quality of life of multiple sclerosis in the United Kingdom.
Kobelt G; Berg J; Lindgren P; Kerrigan J; Russell N; Nixon R
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S96-104. PubMed ID: 17310341
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
